<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="healthcare" lang="en"><front><journal-meta><journal-id journal-id-type="publisher">IJCRR</journal-id><journal-id journal-id-type="nlm-ta">I Journ Cur Res Re</journal-id><journal-title-group><journal-title>International Journal of Current Research and Review</journal-title><abbrev-journal-title abbrev-type="pubmed">I Journ Cur Res Re</abbrev-journal-title></journal-title-group><issn pub-type="ppub">2231-2196</issn><issn pub-type="opub">0975-5241</issn><publisher><publisher-name>Radiance Research Academy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">4221</article-id><article-id pub-id-type="doi"/><article-id pub-id-type="doi-url"> http://dx.doi.org/10.31782/IJCRR.2021.132204</article-id><article-categories><subj-group subj-group-type="heading"><subject>Healthcare</subject></subj-group></article-categories><title-group><article-title>&#13;
	Expression of Estrogen and Progesterone Receptors in Ovarian Neoplasms&#13;
&#13;
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>aizah</surname><given-names>F</given-names></name></contrib><contrib contrib-type="author"><name><surname>Rizwan</surname><given-names>Aziz Mir</given-names></name></contrib><contrib contrib-type="author"><name><surname>Uma</surname><given-names>Sharma</given-names></name></contrib></contrib-group><pub-date pub-type="ppub"><day>20</day><month>11</month><year>2021</year></pub-date><volume>2)</volume><issue/><fpage>12</fpage><lpage>16</lpage><permissions><copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p></license></permissions><abstract><p>&#13;
	Introduction: Ovarian cancer is one of the most aggressive malignancies of the female reproductive system and is the seventh most common cause of cancer-related deaths in females constituting about 4.0% of all female malignancies. Among cancers of the female genital tract, the incidence of ovarian cancer rank below only carcinoma of the cervix and the endometrium. Aim of the Study: The study aims to analyze the expression of estrogen receptor (ER) and progesterone receptor (PR) immunohistochemical markers in ovarian neoplasms and correlate these with age, histological type and grade of the tumour. Material and Methods: A retro-prospective study was conducted in the Pathology department of our institution for a period of 1 year, from April 2019 to March 2020. 57 cases of ovarian tumours were studied. Haematoxylin __ampersandsignamp; Eosin staining was done followed by immunohistochemical staining for ER and PR. Results: Most of the tumours were benign and serous tumours were the most common histopathological entity. Expression of ER was more in malignant tumours (76.92%) than borderline (66.66%) and benign tumours (53.65%). The expression of PR was more in benign (60.97%) than borderline (33.33%) and malignant (38.41 %) tumours. Conclusion: ER expression was more in malignant tumours and PR expression was a more prevalent feature of benign tumors. This may support the role of estrogen in oncogenesis and indicate a protective role of progesterone in the development of ovarian carcinomas.&#13;
&#13;
</p></abstract><kwd-group><kwd>Estrogen</kwd><kwd> Neoplasm</kwd><kwd> Ovarian</kwd><kwd> Progesterone</kwd><kwd> Reproductive system</kwd><kwd> IHC</kwd></kwd-group></article-meta></front></article>
